FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

27 letters match. Newest first.

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Walmart, Inc.

    Walmart sold three unapproved drugs for genital herpes and sores on walmart.com, FDA says.

    High risk
  3. The Platinum Healthcare LLC

    The Platinum Healthcare LLC sells unapproved new drugs 'Sycosis' and 'Syphillinum' online for STIs, FDA warns.

    High risk
  4. Aidance Scientific, Inc.

    FDA: Aidance Scientific's Terragen HG Formula, sold for genital sores, is an unapproved new drug.

    High risk
  5. OrganiCare, LLC / OrganiCare Nature’s Science, LLC

    FDA told OrganiCare of Austin, Texas that its HClear for him and FemiClear Genital Herpes Symptoms ointments are unapproved new drugs.

    High risk
  6. DesBio/Deseret Biologicals, Inc.

    FDA says DesBio’s CHLA:10M, sold online for Chlamydia symptoms, is an unapproved new drug.

    High risk
  7. Indiangoods.shop

    FDA warned website Indiangoods.shop that three herbal sexual-performance capsules it sells are unapproved new drugs.

    Medium
  8. Wholesale Peptide

    FDA warns Wholesale Peptide that its website sells Prostamax and Gonadorelin as unapproved new drugs.

    High risk
  9. Texinkart Inc.

    Texinkart Inc. sold four Ayurvedic products online without FDA drug approval, FDA says.

    High risk
  10. NativeMed LLC dba NativeMed

    FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  11. Glow Medispa, LLC dba Mint Med

    FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.

    Low
  12. D&H Medical Services

    FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.

    Low
  13. OrderlyMeds LLC dba OrderlyMeds

    FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.

    Low
  14. Joi and Blokes dba Joi + Blokes

    FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.

    Medium
  15. Clover Meds LLC dba Clover Meds

    Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.

    Medium
  16. Ridley USA Inc.

    Ridley USA's Iowa City medicated feed plant put monensin into cattle feed instead of the intended drug, killing at least 16 cattle.

    High risk
  17. Mile High Compounds LLC

    FDA warned Mile High Compounds that it sells unapproved injectable GLP-1-like drugs and BAC water online.

    High risk
  18. Weightless Medical LLC dba WeightCare

    FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.

    Low
  19. Viv Health, Inc. dba VIV RX

    FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  20. Ivim Services LLC dba Ivim

    FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.

    Low
  21. MaxLife Technologies Inc. dba Maxlife

    FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.

    Medium
  22. Better Health Labs, Inc. dba Measured

    FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.

    Medium
  23. MEDVi, LLC dba MEDVi

    FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.

    Medium
  24. Newman Clinic, PLLC dba Newman Clinic

    FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  25. Bliv Wellness LLC dba Bliv

    FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  26. Beach Weekend Management LLC dba Nic and Jet Fuel

    FDA told Nic and Jet Fuel its nicotine energy drinks are unapproved new drugs sold with drug-like claims.

    Medium
  27. Palamur Biosciences Private Limited

    FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.

    High risk